Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection

Background: Helicobacter pylori eradication rates achieved with clarithromycin-based triple therapies are declining due to antibiotic resistance, but data regarding temporal changes in efficacy with these eradication therapies are scarce. Objective: To evaluate the efficacy of clarithromycin-based triple eradication regimens over time. Design: A comprehensive literature review and time-trend analysis. Data sources and methods: Bibliographies of recently published systematic literature reviews were searched and supplemented with a targeted literature review conducted using Medline and Embase databases and ProQuest from conception to May 2021. Studies reporting H. pylori eradication rates of clarithromycin-based triple therapies were included and temporal trends were estimated using a random-effects model. Results: Eradication rates for triple therapies containing proton pump inhibitors (PPIs), clarithromycin, and amoxicillin showed a significant decline over the past 23 years (p = 0.0315). However, this decline was not significant when eradication rates achieved with vonoprazan-based triple therapy were included (p = 0.3910). Conclusion: Vonoprazan-based triple therapy partially mitigated the decline in eradication rates seen with PPI-based triple therapy, likely due to more powerful acid suppression of vonoprazan.

[1]  P. Malfertheiner,et al.  Potassium-competitive acid blocker and proton pump inhibitor-based regimens for first-line Helicobacter pylori eradication: a network meta-analysis , 2022, Gastro Hep Advances.

[2]  S. Moss,et al.  Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis , 2022, The American journal of gastroenterology.

[3]  R. Yadlapati,et al.  Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure , 2022, Expert review of gastroenterology & hepatology.

[4]  H. Goossens,et al.  Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community , 2021, Gut.

[5]  P. Malfertheiner,et al.  Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: a Network Meta-Analysis. , 2021, Gastroenterology.

[6]  D. Graham,et al.  PRIMER FOR DEVELOPMENT OF GUIDELINES FOR HELICOBACTER PYLORI THERAPY USING ANTIBIOTIC STEWARDSHIP. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  T. Gotoda,et al.  Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan , 2020, Gut.

[8]  D. Graham,et al.  Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. , 2018, Gastroenterology.

[9]  S. Maeda,et al.  Vonoprazan‐ vs proton‐pump inhibitor‐based first‐line 7‐day triple therapy for clarithromycin‐susceptible Helicobacter pylori: A multicenter, prospective, randomized trial , 2018, Helicobacter.

[10]  S. Ng,et al.  Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. , 2017, Gastroenterology.

[11]  N. Tanaka,et al.  Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial , 2017, Canadian journal of gastroenterology & hepatology.

[12]  W. Chey,et al.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection , 2017, The American Journal of Gastroenterology.

[13]  R. Hunt,et al.  Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report , 2016, Gut.

[14]  R. Harbour,et al.  Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis , 2016, BMC Gastroenterology.

[15]  H. Echizen.  The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations , 2016, Clinical Pharmacokinetics.

[16]  K. Murakami,et al.  Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study , 2016, Gut.

[17]  Jason Y. Park,et al.  Review article: the global emergence of Helicobacter pylori antibiotic resistance , 2015, Alimentary pharmacology & therapeutics.

[18]  H. E. Leylabadlo,et al.  Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. , 2015, World journal of methodology.

[19]  M. Alboraie,et al.  Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait. , 2015, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[20]  P. Malfertheiner,et al.  Kyoto global consensus report on Helicobacter pylori gastritis , 2015, Gut.

[21]  K. Sugano.  [Vonoprazan: a novel potassium-competitive acid blocker]. , 2015, Nihon rinsho. Japanese journal of clinical medicine.

[22]  A. Inoue,et al.  Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. , 2014, World journal of gastroenterology.

[23]  Deng-Chyang Wu,et al.  Randomized trial comparing rabeprazole‐ versus lansoprazole‐based Helicobacter pylori eradication regimens , 2013, The Kaohsiung journal of medical sciences.

[24]  Q. Mei,et al.  The effect of cytochrome P2C19 and interleukin‐1 polymorphisms on H. pylori eradication rate of 1‐week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people , 2010, Journal of clinical pharmacy and therapeutics.

[25]  D. Graham,et al.  Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. , 2010, Gastroenterology clinics of North America.

[26]  V. Lee,et al.  Pharmacogenetics of esomeprazole or rabeprazole‐based triple therapy in Helicobacter pylori eradication in Hong Kong non‐ulcer dyspepsia Chinese subjects , 2010, Journal of clinical pharmacy and therapeutics.

[27]  Y. Songür,et al.  Triple or Quadruple Tetracycline-Based Therapies Versus Standard Triple Treatment for Helicobacter pylori Treatment , 2009, The American journal of the medical sciences.

[28]  S. Ching,et al.  Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. , 2008, World journal of gastroenterology.

[29]  Y. Cho,et al.  Double‐Dose, New‐Generation Proton Pump Inhibitors Do Not Improve Helicobacter pylori Eradication Rate , 2007, Helicobacter.

[30]  A. Uygun,et al.  The efficacy of bismuth containing quadruple therapy as a first‐line treatment option for Helicobacter pylori , 2007, Journal of digestive diseases.

[31]  I. Subei,et al.  One Week of Esomeprazole Triple Therapy vs. 1 Week of Omeprazole Triple Therapy Plus 3 Weeks of Omeprazole for Duodenal Ulcer Healding in Helicobacter pylori-Positive Patients , 2007, Digestive Diseases and Sciences.

[32]  A. Kao,et al.  Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism , 2005 .

[33]  G. Anagnostopoulos,et al.  Esomeprazole versus Omeprazole for the Eradication of Helicobacter pylori Infection: Results of a Randomized Controlled Study , 2004, Journal of clinical gastroenterology.

[34]  U. Kachintorn,et al.  Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection , 2003, Alimentary pharmacology & therapeutics.

[35]  S. Ishihara,et al.  Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment. , 2003, Current therapeutic research, clinical and experimental.

[36]  J. Atherton,et al.  Safety and efficacy of 7‐day rabeprazole‐ and omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease , 2003, Alimentary pharmacology & therapeutics.

[37]  M. Kasuga,et al.  Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan , 2003, European journal of gastroenterology & hepatology.

[38]  K. Murakami,et al.  Eradication rates of clarithromycin‐resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin , 2002, Alimentary pharmacology & therapeutics.

[39]  K. Petraki,et al.  Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study , 2002, European journal of gastroenterology & hepatology.

[40]  K. Yokota,et al.  Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype , 2002, Journal of gastroenterology and hepatology.

[41]  X. Calvet,et al.  One‐week triple vs. quadruple therapy for Helicobacter pylori infection — a randomized trial , 2002, Alimentary pharmacology & therapeutics.

[42]  Z. Tulassay,et al.  One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease , 2001, European journal of gastroenterology & hepatology.

[43]  T. Azuma,et al.  Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[44]  K. Lauritsen,et al.  One‐week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease , 2000, Alimentary pharmacology & therapeutics.

[45]  N. Sato,et al.  Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection—comparison with omeprazole and lansoprazole , 1999, Alimentary pharmacology & therapeutics.

[46]  N. Sato,et al.  Efficacy of 1 week omeprazole or lansoprazole– amoxycillin–clarithromycin therapy for Helicobacter pylori infection in the Japanese population , 1999, Journal of gastroenterology and hepatology.

[47]  R. Spiller,et al.  The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. , 1999, Gastroenterology.

[48]  Colombo,et al.  Comparison of omeprazole and lansoprazole in short‐term triple therapy for Helicobacter pylori infection , 1998, Alimentary pharmacology & therapeutics.

[49]  J. Freston,et al.  Triple Versus Dual Therapy for Eradicating Helicobacter pylori and Preventing Ulcer Recurrence: A Randomized, Double-Blind, Multicenter Study of Lansoprazole, Clarithromycin, and/or Amoxicillin in Different Dosing Regimens , 1998, American Journal of Gastroenterology.

[50]  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. , 1997, Gut.

[51]  H. Chun,et al.  Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea. , 2012, British journal of clinical pharmacology.

[52]  Y. Takei,et al.  Efficacy of Reduced Dosage of Rabeprazole in PPI/AC Therapy for Helicobacter pylori Infection , 2004, Digestive Diseases and Sciences.

[53]  R. Spiller,et al.  The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. , 1997, The Journal of antimicrobial chemotherapy.